Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SoftMedX Healthcare's annualized net income for the quarter that ended in Jun. 2026 was HK$9.30 Mil. SoftMedX Healthcare's average shareholder tangible equity for the quarter that ended in Jun. 2026 was HK$29.81 Mil. Therefore, SoftMedX Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 31.18%.
The historical rank and industry rank for SoftMedX Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:00648'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -468.74 Med: -144.97 Max: 46.55
Current: 37.8
During the past 13 years, SoftMedX Healthcare's highest Return-on-Tangible-Equity was 46.55%. The lowest was -468.74%. And the median was -144.97%.
HKSE:00648's Return-on-Tangible-Equity is ranked better than 80.03% of 581
companies
in the Healthcare Providers & Services industry
Industry Median: 10.72
vs HKSE:00648: 37.80
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SoftMedX Healthcare Return-on-Tangible-Equity Related Terms
SoftMedX Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SoftMedX Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00648 vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, SoftMedX Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SoftMedX Healthcare Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SoftMedX Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SoftMedX Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 31.18% mean?
SoftMedX Healthcare (HKSE:00648) has a Return-on-Tangible-Equity of 31.18% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SoftMedX Healthcare and its competitors. According to the industry distribution chart, SoftMedX Healthcare ranks #116 out of 581 companies in the Healthcare Providers & Services industry, placing it in the top 20%.
Is SoftMedX Healthcare's Return-on-Tangible-Equity too high?
SoftMedX Healthcare's current Return-on-Tangible-Equity is 31.18%. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.72. SoftMedX Healthcare's value of 31.18% is 190.9% above this industry median. Based on the distribution chart, SoftMedX Healthcare ranks #116 out of 581 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, SoftMedX Healthcare has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SoftMedX Healthcare's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, SoftMedX Healthcare ranks #116 out of 581 companies for Return-on-Tangible-Equity. This places SoftMedX Healthcare in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.72. SoftMedX Healthcare's value of 31.18% is 190.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.72, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SoftMedX Healthcare's current Return-on-Tangible-Equity of 31.18% is 190.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SoftMedX Healthcare and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SoftMedX Healthcare's current Return-on-Tangible-Equity is 31.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SoftMedX Healthcare stock overvalued right now?
Based on GuruFocus' analysis, SoftMedX Healthcare (HKSE:00648) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.52, compared to a current price of HK$0.59 — trading 76.6% below its estimated fair value. The current Return-on-Tangible-Equity is 31.18% and 190.9% above the Healthcare Providers & Services industry median of 10.72. SoftMedX Healthcare's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SoftMedX Healthcare (HKSE:00648), the current Return-on-Tangible-Equity is 31.18% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SoftMedX Healthcare (HKSE:00648) Overvalued in 2026?
Based on GuruFocus' analysis, SoftMedX Healthcare stock appears to be undervalued.
The current stock price of HK$0.59 is trading 76.6% below its estimated GF Value™ of HK$2.52.
GuruFocus considers SoftMedX Healthcare to be Possible Value Trap.
Key valuation signals for HKSE:00648:
Return-on-Tangible-Equity: 31.18%
GF Value™: HK$2.52 vs. price of HK$0.59 (76.6% below fair value)
Industry Position: 190.9% above the Healthcare Providers & Services median (#116 of 581)
No single metric tells the full story. See the HKSE:00648 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SoftMedX Healthcare Ltd is principally engaged in the distribution of medical and healthcare equipment and products. The Group has one reportable operating segment: medical and well-being business, for the Distribution of medical and healthcare equipment and products.
54GF Score
Get the complete analysis for HKSE:00648
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00648 has been successfully added to your 
